Catalyst Event
Shanghai Fosun Pharmaceutical (Group) Co Ltd (2196) · Other
From Akros SCHK HK-Global Genomics Index (ASHGGENM)
5/29/2026, 12:00:00 AM
Announced that subsidiary Shanghai Henlius Biotech's Pertuzumab Injection (brand name 汉倍优®) was approved for marketing by China's NMPA. Low importance as subsidiary product approvals typically have a limited price impact (<5%).
Korean Translation
자회사 상하이 헨리우스 바이오텍의 유방암 치료용 바이오시밀러 퍼투주맙 주사제(브랜드명 汉倍优®)가 중국 NMPA 판매 허가를 획득함. 자회사 제품 허가에 따른 주가 영향은 1~5% 수준으로 제한적일 것으로 예상됨.
Related Recent Events
Pacific Biosciences of California Inc (PACB) · Earnings Release
Q2 2026 earnings release is scheduled.
8/6/2026, 12:00:00 AM
Pharmaron Beijing Co Ltd (3759) · Other
The ex-dividend date for the RMB 0.20 per share final dividend on July 7, 2026, with payment on August 7, 2026; market reaction is estimated at Low as the payout is within expected ranges scheduled.
7/7/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Ex-dividend date on 2026-06-29 for the 2025 final dividend of HK$0.0418 per share; Low importance justified by it being a standard technical adjustment scheduled
6/29/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Annual General Meeting on June 26, 2026, to approve 2025 results and dividends. Analysts estimate a 1-5% price impact for this routine corporate event scheduled.
6/26/2026, 12:00:00 AM
Jinxin Fertility Group Limited (1951) · Other
Annual General Meeting on 2026-06-25 to vote on 2025 financial statements and a HK$0.0418 dividend; Low importance justified by the routine nature of the meeting scheduled
6/25/2026, 12:00:00 AM
Biocytogen Pharmaceuticals (Beijing) Co Ltd (2315) · Other
An extraordinary general meeting is scheduled on 2026-06-25 to vote on a new executive remuneration system and a 10% H-share repurchase mandate; 1% price impact expected.
6/25/2026, 12:00:00 AM